Zoll receives FDA Clearance to market E Series Monitor Defibrillator with CO Measurement

ZOLL Medical Corporation, a manufacturer of resuscitation devices and related software solutions, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new model of the ZOLL E Series Monitor/Defibrillator with carbon monoxide (CO) measurement.  The product is immediately available for shipment.

CO measurement is a breakthrough that helps rescuers noninvasively and immediately diagnose, monitor, and treat patients poisoned by this “silent killer.” CO poisoning can present with flu-like symptoms, but it is also possible to be affected without having any symptoms at all.1 Undetected, untreated episodes can lead to permanent neurological and cardiac damage, and often death.

In firefighters, even mild CO poisoning causes mental confusion, which can put both the exposed rescuer and others on the fire scene at risk.2  Consistent exposure to CO may cause long term heart and brain damage.3  In addition, for both firefighters and civilians, just one severe incident of CO poisoning almost doubles the risk of premature death.4

Now with integrated Masimo® CO-Oximetry® carbon monoxide measurement, the E Series allows rescuers to easily and accurately diagnose CO poisoning with the simple push of a button. Recognition is the key to immediate on-scene treatment. With early detection, treatment for CO poisoning can begin immediately, which significantly reduces immediate and long-term health risks for both firefighters and the civilians whom they serve.